Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (127)

Jul 17, 2038method-of-use (U-4220)US 12350262
Jul 17, 2038method-of-use (U-4221)US 12350262
Jul 17, 2038method-of-use (U-4222)US 12350262
Dec 8, 2037compositionUS 10793547
Dec 8, 2037compositionUS 10793547
Dec 8, 2037compositionUS 10793547
Dec 8, 2037compositionUS 10793547
Dec 8, 2037formulationUS 11179367
Dec 8, 2037formulationUS 11179367
Dec 8, 2037formulationUS 11179367
Dec 8, 2037formulationUS 11179367
Dec 8, 2037compositionUS 11453655
Dec 8, 2037compositionUS 11453655
Dec 8, 2037compositionUS 11453655
Dec 8, 2037compositionUS 11453655
Dec 8, 2037formulationUS 11517564
Dec 8, 2037formulationUS 11517564
Dec 8, 2037formulationUS 11517564
Dec 8, 2037formulationUS 11517564
Oct 6, 2035compositionUS 10758534
Oct 6, 2035compositionUS 10758534
Oct 6, 2035compositionUS 10758534
Oct 6, 2035compositionUS 10758534
Oct 6, 2035compositionUS 11426407
Oct 6, 2035compositionUS 11426407
Oct 6, 2035compositionUS 11426407
Oct 6, 2035compositionUS 11426407
Jul 15, 2033method-of-use (U-3154)US 9012496
Jul 15, 2033method-of-use (U-3154)US 9012496
Feb 27, 2033formulationUS 10272046
Feb 27, 2033formulationUS 10272046
Feb 27, 2033formulationUS 11147770
Feb 27, 2033formulationUS 11147770
Feb 27, 2033formulationUS 11752106
Feb 27, 2033formulationUS 11752106
Feb 27, 2033formulationUS 12214083
Feb 27, 2033formulationUS 12214083
Feb 27, 2033formulationUS 8883206
Feb 27, 2033formulationUS 8883206
Jul 10, 2031compositionUS RE504534.8y
Jul 10, 2031compositionUS RE504534.8y
Jul 10, 2031compositionUS RE504534.8y
Jul 10, 2031compositionUS RE504534.8y
Mar 25, 2031formulationUS 100816214.5y
Mar 25, 2031formulationUS 100816214.5y
Mar 25, 2031formulationUS 100816214.5y
Mar 25, 2031formulationUS 100816214.5y
Mar 25, 2031formulationUS 115780624.5y
Mar 25, 2031formulationUS 115780624.5y
Mar 25, 2031formulationUS 115780624.5y
Mar 25, 2031formulationUS 115780624.5y
Aug 13, 2029formulationUS 106464812.9y
Aug 13, 2029formulationUS 106464812.9y
Aug 13, 2029formulationUS 106464812.9y
Aug 13, 2029formulationUS 106464812.9y
Aug 13, 2029method-of-use (U-4055)US 115649162.9y
Aug 13, 2029method-of-use (U-4063)US 115649162.9y
Aug 13, 2029method-of-use (U-4063)US 115649162.9y
Aug 13, 2029method-of-use (U-4055)US 115649162.9y
Aug 13, 2029formulationUS 124586352.9y
Aug 13, 2029formulationUS 124586352.9y
Aug 13, 2029formulationUS 124586352.9y
Aug 13, 2029formulationUS 124586352.9y
Nov 12, 2027method-of-use (U-4066)US 84153871.1y
Nov 12, 2027method-of-use (U-3144)US 84153871.1y
Nov 12, 2027method-of-use (U-4066)US 84153871.1y
Nov 12, 2027method-of-use (U-3144)US 84153871.1y
Aug 5, 2027method-of-use (U-3144)US 8324242303d
Aug 5, 2027method-of-use (U-3144)US 8324242303d
Aug 5, 2027method-of-use (U-3589)US 8324242303d
Aug 5, 2027method-of-use (U-3589)US 8324242303d
Jun 3, 2027compositionUS 7776905240d
Jun 3, 2027compositionUS 7776905240d
Jun 3, 2027compositionUS 7776905240d
Jun 3, 2027compositionUS 7776905240d
May 20, 2027compositionUS 7495103226d
May 20, 2027compositionUS 7495103226d
May 20, 2027compositionUS 7495103226d
May 20, 2027compositionUS 7495103226d
May 1, 2027compositionUS 7645789207d
May 1, 2027compositionUS 7645789207d
May 1, 2027compositionUS 7645789207d
May 1, 2027compositionUS 7645789207d
May 1, 2027method-of-use (U-3589)US 8598181207d
May 1, 2027method-of-use (U-4056)US 8598181207d
May 1, 2027method-of-use (U-4056)US 8598181207d
May 1, 2027method-of-use (U-3589)US 8598181207d
May 1, 2027compositionUS 8623905207d
May 1, 2027compositionUS 8623905207d
May 1, 2027compositionUS 8623905207d
May 1, 2027compositionUS 8623905207d
Apr 9, 2027formulationUS 10022352185d
Apr 9, 2027formulationUS 10022352185d
Apr 9, 2027formulationUS 10022352185d
Apr 9, 2027formulationUS 10022352185d
Apr 9, 2027compositionUS 10239867185d
Apr 9, 2027compositionUS 10239867185d
Apr 9, 2027compositionUS 10239867185d
Apr 9, 2027compositionUS 10239867185d
Apr 9, 2027compositionUS 11639347185d
Apr 9, 2027compositionUS 11639347185d
Apr 9, 2027compositionUS 11639347185d
Apr 9, 2027compositionUS 11639347185d
Apr 9, 2027formulationUS 9974781185d
Apr 9, 2027formulationUS 9974781185d
Apr 9, 2027formulationUS 9974781185d
Apr 9, 2027formulationUS 9974781185d
Dec 28, 2026formulationUS 841027483d
Dec 28, 2026formulationUS 841027483d
Dec 28, 2026formulationUS 841027483d
Dec 28, 2026formulationUS 841027483d
Dec 28, 2026compositionUS 875422483d
Dec 28, 2026compositionUS 875422483d
Dec 28, 2026compositionUS 875422483d
Dec 28, 2026compositionUS 875422483d
Dec 28, 2026formulationUS 967016383d
Dec 28, 2026formulationUS 967016383d
Dec 28, 2026formulationUS 967016383d
Dec 28, 2026formulationUS 967016383d
Dec 28, 2026formulationUS 993133483d
Dec 28, 2026formulationUS 993133483d
Dec 28, 2026formulationUS 993133483d
Dec 28, 2026formulationUS 993133483d
Jul 6, 2026method-of-use (U-3593)US 8354427
Jul 6, 2026method-of-use (U-3145)US 8354427
Jul 6, 2026method-of-use (U-3145)US 8354427
Jul 6, 2026method-of-use (U-3593)US 8354427

FDA exclusivities (17)

Dec 20, 2031ODE-512Orphan Drug (7y)
Dec 20, 2031ODE-512Orphan Drug (7y)
Dec 20, 2031ODE-512Orphan Drug (7y)
Dec 20, 2031ODE-512Orphan Drug (7y)
Apr 26, 2030ODE-433Orphan Drug (7y)3.6y
Apr 26, 2030ODE-433Orphan Drug (7y)3.6y
Jun 8, 2028ODE-357Orphan Drug (7y)1.7y
Jun 8, 2028ODE-357Orphan Drug (7y)1.7y
Dec 21, 2027ODE-323Orphan Drug (7y)1.2y
Dec 21, 2027ODE*ODE*1.2y
Dec 20, 2027M-313Method (3y)1.2y
Dec 20, 2027M-313Method (3y)1.2y
Dec 20, 2027M-313Method (3y)1.2y
Oct 21, 2026ODE-275Orphan Drug (7y)15d
Oct 21, 2026ODE*ODE*15d
Apr 26, 2026NPNP
Apr 26, 2026NPNP

News(0)

no news has mentioned this drug yet

Data sources

openFDA · ClinicalTrials.gov

last refreshed 4h ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

drug

save

TRIKAFTA (COPACKAGED)

Marketedupdated 5mo ago

by $VERX Vertex, Inc.

Approved

community read0 votes

🐶 often sniffed alongside

top 7

all catalysts(19)

approval · 19

TRIKAFTA (COPACKAGED) (ELEXACAFTOR, IVACAFTOR, TEZACAFTOR) — FDA approval

TRIKAFTA (COPACKAGED)

TRIKAFTA (COPACKAGED) (ELEXACAFTOR, IVACAFTOR, TEZACAFTOR) — FDA approval

TRIKAFTA (COPACKAGED)

TRIKAFTA (COPACKAGED) (ELEXACAFTOR, IVACAFTOR, TEZACAFTOR) — FDA approval

TRIKAFTA (COPACKAGED)

TRIKAFTA (COPACKAGED) (ELEXACAFTOR, IVACAFTOR, TEZACAFTOR) — FDA approval

TRIKAFTA (COPACKAGED)

TRIKAFTA (COPACKAGED) (ELEXACAFTOR, IVACAFTOR, TEZACAFTOR) — FDA approval

TRIKAFTA (COPACKAGED)

TRIKAFTA (COPACKAGED) (ELEXACAFTOR, IVACAFTOR, TEZACAFTOR) — FDA approval

TRIKAFTA (COPACKAGED)

TRIKAFTA (COPACKAGED) (ELEXACAFTOR, IVACAFTOR, TEZACAFTOR) — FDA approval

TRIKAFTA (COPACKAGED)

TRIKAFTA (COPACKAGED) (ELEXACAFTOR, IVACAFTOR, TEZACAFTOR) — FDA approval

TRIKAFTA (COPACKAGED)

TRIKAFTA (COPACKAGED) (ELEXACAFTOR, IVACAFTOR, TEZACAFTOR) — FDA approval

TRIKAFTA (COPACKAGED)

TRIKAFTA (COPACKAGED) (ELEXACAFTOR, IVACAFTOR, TEZACAFTOR) — FDA approval

TRIKAFTA (COPACKAGED)

TRIKAFTA (COPACKAGED) (ELEXACAFTOR, IVACAFTOR, TEZACAFTOR) — FDA approval

TRIKAFTA (COPACKAGED)

TRIKAFTA (COPACKAGED) (ELEXACAFTOR, IVACAFTOR, TEZACAFTOR) — FDA approval

TRIKAFTA (COPACKAGED)

TRIKAFTA (COPACKAGED) (ELEXACAFTOR, IVACAFTOR, TEZACAFTOR) — FDA approval

TRIKAFTA (COPACKAGED)

TRIKAFTA (COPACKAGED) (ELEXACAFTOR, IVACAFTOR, TEZACAFTOR) — FDA approval

TRIKAFTA (COPACKAGED)

TRIKAFTA (COPACKAGED) (ELEXACAFTOR, IVACAFTOR, TEZACAFTOR) — FDA approval

TRIKAFTA (COPACKAGED)

TRIKAFTA (COPACKAGED) (ELEXACAFTOR, IVACAFTOR, TEZACAFTOR) — FDA approval

TRIKAFTA (COPACKAGED)

TRIKAFTA (COPACKAGED) (ELEXACAFTOR, IVACAFTOR, TEZACAFTOR) — FDA approval

TRIKAFTA (COPACKAGED)

TRIKAFTA (COPACKAGED) (ELEXACAFTOR, IVACAFTOR, TEZACAFTOR) — FDA approval

TRIKAFTA (COPACKAGED)

TRIKAFTA (COPACKAGED) (ELEXACAFTOR, IVACAFTOR, TEZACAFTOR) — FDA approval

TRIKAFTA (COPACKAGED)

→

view all 19 catalysts →

Patent cliff

source: FDA Orange Book

first barrier falls

Oct 21, 2026

15 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (127)

Jul 17, 2038method-of-use (U-4220)US 12350262
Jul 17, 2038method-of-use (U-4221)US 12350262
Jul 17, 2038method-of-use (U-4222)US 12350262
Dec 8, 2037compositionUS 10793547
Dec 8, 2037compositionUS 10793547
Dec 8, 2037compositionUS 10793547
Dec 8, 2037compositionUS 10793547
Dec 8, 2037formulationUS 11179367
Dec 8, 2037formulationUS 11179367
Dec 8, 2037formulationUS 11179367
Dec 8, 2037formulationUS 11179367
Dec 8, 2037compositionUS 11453655
Dec 8, 2037compositionUS 11453655
Dec 8, 2037compositionUS 11453655
Dec 8, 2037compositionUS 11453655
Dec 8, 2037formulationUS 11517564
Dec 8, 2037formulationUS 11517564
Dec 8, 2037formulationUS 11517564
Dec 8, 2037formulationUS 11517564
Oct 6, 2035compositionUS 10758534
Oct 6, 2035compositionUS 10758534
Oct 6, 2035compositionUS 10758534
Oct 6, 2035compositionUS 10758534
Oct 6, 2035compositionUS 11426407
Oct 6, 2035compositionUS 11426407
Oct 6, 2035compositionUS 11426407
Oct 6, 2035compositionUS 11426407
Jul 15, 2033method-of-use (U-3154)US 9012496
Jul 15, 2033method-of-use (U-3154)US 9012496
Feb 27, 2033formulationUS 10272046
Feb 27, 2033formulationUS 10272046
Feb 27, 2033formulationUS 11147770
Feb 27, 2033formulationUS 11147770
Feb 27, 2033formulationUS 11752106
Feb 27, 2033formulationUS 11752106
Feb 27, 2033formulationUS 12214083
Feb 27, 2033formulationUS 12214083
Feb 27, 2033formulationUS 8883206
Feb 27, 2033formulationUS 8883206
Jul 10, 2031compositionUS RE504534.8y
Jul 10, 2031compositionUS RE504534.8y
Jul 10, 2031compositionUS RE504534.8y
Jul 10, 2031compositionUS RE504534.8y
Mar 25, 2031formulationUS 100816214.5y
Mar 25, 2031formulationUS 100816214.5y
Mar 25, 2031formulationUS 100816214.5y
Mar 25, 2031formulationUS 100816214.5y
Mar 25, 2031formulationUS 115780624.5y
Mar 25, 2031formulationUS 115780624.5y
Mar 25, 2031formulationUS 115780624.5y
Mar 25, 2031formulationUS 115780624.5y
Aug 13, 2029formulationUS 106464812.9y
Aug 13, 2029formulationUS 106464812.9y
Aug 13, 2029formulationUS 106464812.9y
Aug 13, 2029formulationUS 106464812.9y
Aug 13, 2029method-of-use (U-4055)US 115649162.9y
Aug 13, 2029method-of-use (U-4063)US 115649162.9y
Aug 13, 2029method-of-use (U-4063)US 115649162.9y
Aug 13, 2029method-of-use (U-4055)US 115649162.9y
Aug 13, 2029formulationUS 124586352.9y
Aug 13, 2029formulationUS 124586352.9y
Aug 13, 2029formulationUS 124586352.9y
Aug 13, 2029formulationUS 124586352.9y
Nov 12, 2027method-of-use (U-4066)US 84153871.1y
Nov 12, 2027method-of-use (U-3144)US 84153871.1y
Nov 12, 2027method-of-use (U-4066)US 84153871.1y
Nov 12, 2027method-of-use (U-3144)US 84153871.1y
Aug 5, 2027method-of-use (U-3144)US 8324242303d
Aug 5, 2027method-of-use (U-3144)US 8324242303d
Aug 5, 2027method-of-use (U-3589)US 8324242303d
Aug 5, 2027method-of-use (U-3589)US 8324242303d
Jun 3, 2027compositionUS 7776905240d
Jun 3, 2027compositionUS 7776905240d
Jun 3, 2027compositionUS 7776905240d
Jun 3, 2027compositionUS 7776905240d
May 20, 2027compositionUS 7495103226d
May 20, 2027compositionUS 7495103226d
May 20, 2027compositionUS 7495103226d
May 20, 2027compositionUS 7495103226d
May 1, 2027compositionUS 7645789207d
May 1, 2027compositionUS 7645789207d
May 1, 2027compositionUS 7645789207d
May 1, 2027compositionUS 7645789207d
May 1, 2027method-of-use (U-3589)US 8598181207d
May 1, 2027method-of-use (U-4056)US 8598181207d
May 1, 2027method-of-use (U-4056)US 8598181207d
May 1, 2027method-of-use (U-3589)US 8598181207d
May 1, 2027compositionUS 8623905207d
May 1, 2027compositionUS 8623905207d
May 1, 2027compositionUS 8623905207d
May 1, 2027compositionUS 8623905207d
Apr 9, 2027formulationUS 10022352185d
Apr 9, 2027formulationUS 10022352185d
Apr 9, 2027formulationUS 10022352185d
Apr 9, 2027formulationUS 10022352185d
Apr 9, 2027compositionUS 10239867185d
Apr 9, 2027compositionUS 10239867185d
Apr 9, 2027compositionUS 10239867185d
Apr 9, 2027compositionUS 10239867185d
Apr 9, 2027compositionUS 11639347185d
Apr 9, 2027compositionUS 11639347185d
Apr 9, 2027compositionUS 11639347185d
Apr 9, 2027compositionUS 11639347185d
Apr 9, 2027formulationUS 9974781185d
Apr 9, 2027formulationUS 9974781185d
Apr 9, 2027formulationUS 9974781185d
Apr 9, 2027formulationUS 9974781185d
Dec 28, 2026formulationUS 841027483d
Dec 28, 2026formulationUS 841027483d
Dec 28, 2026formulationUS 841027483d
Dec 28, 2026formulationUS 841027483d
Dec 28, 2026compositionUS 875422483d
Dec 28, 2026compositionUS 875422483d
Dec 28, 2026compositionUS 875422483d
Dec 28, 2026compositionUS 875422483d
Dec 28, 2026formulationUS 967016383d
Dec 28, 2026formulationUS 967016383d
Dec 28, 2026formulationUS 967016383d
Dec 28, 2026formulationUS 967016383d
Dec 28, 2026formulationUS 993133483d
Dec 28, 2026formulationUS 993133483d
Dec 28, 2026formulationUS 993133483d
Dec 28, 2026formulationUS 993133483d
Jul 6, 2026method-of-use (U-3593)US 8354427
Jul 6, 2026method-of-use (U-3145)US 8354427
Jul 6, 2026method-of-use (U-3145)US 8354427
Jul 6, 2026method-of-use (U-3593)US 8354427

FDA exclusivities (17)

Dec 20, 2031ODE-512Orphan Drug (7y)
Dec 20, 2031ODE-512Orphan Drug (7y)
Dec 20, 2031ODE-512Orphan Drug (7y)
Dec 20, 2031ODE-512Orphan Drug (7y)
Apr 26, 2030ODE-433Orphan Drug (7y)3.6y
Apr 26, 2030ODE-433Orphan Drug (7y)3.6y
Jun 8, 2028ODE-357Orphan Drug (7y)1.7y
Jun 8, 2028ODE-357Orphan Drug (7y)1.7y
Dec 21, 2027ODE-323Orphan Drug (7y)1.2y
Dec 21, 2027ODE*ODE*1.2y
Dec 20, 2027M-313Method (3y)1.2y
Dec 20, 2027M-313Method (3y)1.2y
Dec 20, 2027M-313Method (3y)1.2y
Oct 21, 2026ODE-275Orphan Drug (7y)15d
Oct 21, 2026ODE*ODE*15d
Apr 26, 2026NPNP
Apr 26, 2026NPNP

News(0)

no news has mentioned this drug yet

Data sources

openFDA · ClinicalTrials.gov

last refreshed 4h ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

TRIKAFTA (COPACKAGED)

🐶 often sniffed alongside

all catalysts(19)

Patent cliff

patents (127)

FDA exclusivities (17)

News(0)

Report a data issue

comments(0)

TRIKAFTA (COPACKAGED)

🐶 often sniffed alongside

all catalysts(19)

Patent cliff

patents (127)

FDA exclusivities (17)

News(0)

Report a data issue

comments(0)